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In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an
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While the first description of the hereditary disease cystic
fibrosis (CF) [1], emphazised fatal congenital steatorrhea and
pancreatic destruction, lung disease has now been recognized to
have the largest impact onmorbidity andmortality in older people
withCF [1]. Lung disease develops as a consequence ofmutations
in the CF transmembrane conductance regulator (CFTR) gene [2],
which encodes a membrane-bound cAMP-regulated chloride
channel: diminished chloride and water secretion leads to viscous
secretions in the affected airways [3,4]. This impairs mucociliary
clearance [3], thereby facilitating chronic bacterial infections,
which may start at a very early age [1,5,6].
Among the bacterial pathogens isolated from airways of CF
patients the triad Haemophilus influenzae, Staphylococcusaureus and Pseudomonas aeruginosa [7,8] has been isolated
most frequently. Infections with some members of the
B. cepacia complex are associated with a markedly shortened
median survival [9]. Other microbial pathogens isolated from
CF patients include Stenotrophomonas maltophilia, Achromo-
bacter xylosoxidans, Mycobacteria ssp., Aspergillus fumigatus
[10] and strict anaerobes [11,12].
P. aeruginosa, a Gram-negative bacterium found in many
natural and man-made water sources, is present in approximately
27%of patients aged 2–5 years and approximately 80%of patients
aged 25–34 years [1]. Thus this opportunistic bacterium pathogen
is regarded as the most important pathogen in CF [13–16].
Respiratory infections with P. aeruginosa are difficult to treat due
to growth of the pathogen in biofilm-like macrocolonies [10,17].
Nevertheless, various treatment strategies have been developed
2 Numbers and letters in parentheses refer to the grading of medical scientific
publications. For details see Table 1.
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on prognosis [10]. The predicted median survival age of CF
individuals in the USA increased from 14 years in 1969 to
36.5 years in 2005, and 43% of patients are 18 years of age or
older [2]. European registries report similar increases in median
survival ages [6,18]. Repeated courses of inhaled antibiotics using
high doses for the treatment of lung disease in CF patients have
been applied increasingly in the last two decades [10]. This
strategy has circumvented the problem of the poor penetration of
intravenously administered antibiotics into lung parenchymal
tissue and bronchial secretions, and their potential systemic
toxicity when given over prolonged periods of time.
One of the most striking characteristics of P. aeruginosa is its
extraordinary capacity to develop resistance to virtually all anti-
pseudomonal agents through the selection of genetic mutations.
Repeated and prolonged treatment strategies may therefore
increase the resistance of the pathogen to the applied antibiotics,
as demonstrated in trials using tobramycin [19], leading to a
strategy of intermittently administration of this drug [14].
Development of antibiotic resistance in P. aeruginosa is also
facilitated by the occurrence of hypermutable (or mutator) strains,
deficient in the DNA mismatch repair system [20,21]. To avoid
the development of resistance and in an attempt to eradicate non-
mucoid P. aeruginosa, many European CF centres started
antibiotic treatment early after the first detection of the pathogen
with great success [22–27]. In CF patients initially colonized with
mucoid P. aeruginosa strains, or patients in whom initially
nonmucoid strains have already switched to mucoid strains, it
may not be possible to eradicate pathogens from their airways.
Chronic airway inflammation is uniformly observed in
patients with CF [10,28,29]. Chronic lung inflammation with
episodes of acute exacerbations initiates several physiological
and metabolic changes with deleterious effects including weight
loss, anorexia, and metabolic breakdown. Thus, as an adjunct to
optimal antibiotic therapy, anti-inflammatory therapy is war-
ranted to avoid a decline in lung function, tissue remodeling and
tissue destruction. Compared to inhaled corticosteroids, the non-
steroidal anti-inflammatory drug ibuprofen gave promising
results in children and adolescents with CF [30,31], while a
phase III trial in CF patients with the LTB4-receptor antagonist
BIIL 284 [32] was terminated due to adverse effects of the drug.
Trials with protease inhibitors including aerosolized recombi-
nant secretory leukocyte protease inhibitor (SLPI) or α1-
proteinase inhibitor (α1-PI) have not been consistently success-
ful [10,33], while antibiotics with anti-inflammatory effects,
such as macrolides, have improved lung function in CF children
and adults, infected with chronic P. aeruginosa [34–36].
One of the open questions in this context is which markers of
inflammation and which diagnostic techniques or molecules
should be employed to monitor the success of anti-inflamma-
tory therapy in people with CF.
Since purulent CF sputum impairs the activity of aerosolized
drugs, administration of aerosolized antibiotics is generally
preceded by physiotherapy, and/or bronchodilatators ormucolytic
agents such as recombinant human deoxyribonuclease (rhDNase,
Dornase alfa) [37,38]. Additionally, drugs improvingmucociliary
clearance such as hypertonic saline may be beneficial [39,40].Since inhalation therapy was discussed as part of a ECFS
Consensus Conference in 1999 [41] and 2003 [10], several new
drug formulations and new inhalation devices have been
developed.Herewe review the current status of inhaledmedication
in CF, including the mechanisms of action of the various drugs,
their optimal administration and important indications, their effects
on lung function, exacerbation rates, survival and quality of life, as
well as side effects. Specifically we address antibiotics, mucoly-
tics/mucous mobilizers, anti-inflammatory drugs, bronchodilators
and combinations of solutions. Additionally, we review the current
knowledge on devices for inhalation therapy with regard to the
characteristics of wet nebulisers, dry-powder inhalers (DPIs) and
metered dose inhalers (pMDIs) and their interaction with the drug
formulation and patients. Finally, we address the subject of testing
new devices before they are introduced onto the market.
2. Inhaled medications
2.1. Antibiotics
2.1.1. Tobramycin
The aminoglycoside tobramycin is a bactericidal drug that
inhibits protein synthesis by irreversibly binding to the 30S
bacterial ribosome. It is active against most Gram-negative bacilli,
but typically displays no significant activity against BCC strains or
S. maltophiliawhile it is active against strains of Enterococcus and
Staphylococcus. Tobramycin Solution for Inhalation (TSI) is
registered as TOBI® (300mg/5ml) in combinationwith a PARILC
PLUS™ reusable jet nebuliser and a suitable compressor resulting
in a flow rate of 4–6 l/min. Additionally, tobramycin is present in
Bramitob® (300mg/4ml) in combinationwith a PARILCPLUS™
reusable jet nebuliser and the PARI TURBO BOY™ compressor.
Uptake across the bacterial cell wall is energy-dependent and
is impaired in anaerobic environments [42]. Thus, the low
oxygen partial pressure in CF sputum plugs [17] may limit the
efficacy of this drug. Tobramycin is positively charged and
thought to be bound in CF airways to the negatively charged
DNA fibers and P. aeruginosa alginate. Despite these con-
siderations, intermittent (28-day on/28-day off) treatment, using
300 mg of tobramycin twice daily, significantly improved lung
function and reduced sputum P. aeruginosa density compared
with placebo in CF patients [43(1a)].2 Increases in lung function
of about 10% at week 20 were most marked in adolescent
patients (aged 13–17 years) and maintained for up to 96 weeks
in an open-label extension study [14(1a)]. Fewer TSI than
placebo recipients required parenteral anti-pseudomonal agents
or hospitalisation [44(2b),45(2b),46]. Two open-label uncon-
trolled trials have shown that aerosolized tobramycin safely
eradicated P. aeruginosa in the majority of CF patients for up to
three months [24(2b),27(2b)]. P. aeruginosa eradication was
associated with reduced neutrophilic airway inflammation.
TSI is generally well tolerated. Renal toxicity or hearing loss
has not been reported in clinical trials, although transient mild or
moderate tinnitus occurred more frequently in TSI than placebo
Table 1
Grading of medical scientific publications.
Level Description
1a Systemic review of 2 or more unrelated randomised controlled
trials of level 1b.
1b Individual randomised controlled trial of good quality and
sufficient patient numbers included
2a Systemic review cohort studies of level 2b
2b Individual cohort study (including low quality RCT; e.g.,
b80% follow-up)
3a Systemic review of case–control studies of level 3b
3b Individual case–control study
4 Case-series (and poor quality cohort and case–control studies)
5 Expert opinion without explicit critical appraisal, or based
on physiology, bench research or “first principles”
Ref: Oxford Centre for Evidence-based Medicine Levels of Evidence (May
2001).
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TSI has been reported in both preservative-free TSI and tobra-
mycin solutions containing preservatives such as phenol [47
(2b)]. The use of inhaled beta-agonists may prevent the post-
inhalation decline in lung function [47(2b),48(2b)].
2.1.2. Colistimethate sodium
Colistimethate sodium (Colomycin®, Promixin®) is a cyclic
polypeptide antibiotic, derived from Bacillus polymyxa varietas
colistinus, and belongs to the polymyxin group. Due to their
cationic nature, polymyxin antibiotics can damage cell mem-
branes and are bactericidal for Gram-negative bacteria. There
are no specific requirements concerning inhalation devices for
colistimethate sodium and thus the drug can be administered by
ultrasonic or jet nebulisers or by vibrating mesh devices.
Although colistimethate sodium for inhalation has been
prescribed for more than 20 years in people with CF for the
treatment of P. aeruginosa infections, controlled trials are few. A
trial in 40 CF patients showed that inhalation with colistimethate
sodium reduces symptom scores and may have a protective
effect on lung function [49(2b)]. When colistimethate sodium
was compared with TSI, the latter drug was superior, concerning
lung function improvement, while both treatment regimens
decreased P. aeruginosa sputum density [50(2b),51(2b)]. The
greater improvement in lung function seen with TSI might have
resulted from the fact that all patients had previously used
colistimethate sodium but were naïve to TSI. Also the dose of
colistimethate sodium used in the trial (80 mg twice daily) was
lower than most physicians would prescribe in adult CF patients.
Finally, results were only reported for a half cycle of TSI as the
study was not continued for the month off. In combination with
oral ciprofloxacin inhaled colistimethate sodium effectively
eradicated P. aeruginosa for a period of 24 months in more than
80% of treated CF patients [52(2b)]. A European wide
randomized double-blinded phase III study of colistimethate
sodium administered by a dry-powder inhaler (Colobreathe®)
has been carried out but results have not been reported to date.
Colistimethate sodium is generally well tolerated in CF
patients. However, bronchoconstriction following inhalation is
quite common, especially in CF patients, suffering from asthmaor airway hyperresponsiveness [53(2b),54(2b)]. Colistimethate
sodium must be inhaled promptly after reconstitution, since
after prolonged times, the drug is hydrolyzed into the bases
colistin A (polymyxin E1) and colistin B (polymyxin E2).
Polymyxin E1 has been shown in animal studies to cause
localized airway inflammation and eosinophilic infiltration
(FDA, 2007). Colistin (sulfate) is not suitable for treating CF
patients due to severe adverse effects [55].
2.1.3. Aztreonam lysine
Aztreonam is a synthetic monobactam (monocyclic beta-
lactam) antibiotic, which is active against Gram-negative
aerobic organisms and stable to most β-lactamases. Aztreonam
inhibits synthesis of bacterial cell walls and has shown to
produce clinically significant synergy with aminoglycosides
against P. aeruginosa. Aztreonam lysine (AZLI) is a new,
currently unlicensed, formulation for aerosolized treatment of
P. aeruginosa infection in CF patients. The AZLI formulation
makes this compound safe for inhalation, whereas inhalation of
aztreonam arginine, used for intravenous treatment, can cause
airway inflammation after chronic inhalation therapy in CF
patients [56(1b)]. It is delivered by the eFlow® electronic ne-
buliser which produces an aerosol with a narrow size distri-
bution allowing peripheral lung deposition after 2 min of
inhalation [57].
A double-blind, placebo-controlled, dose-escalation Phase
1b trial of single daily doses of 75 mg, 150 mg and 225mgAZLI
or placebo, self-administered by clinically stable CF patients
N12 years of age, showed retention of anti-pseudomonal activity
after nebulisation and no inhibition by CF sputum [58(1b)].
AZLl was active against multiply resistant P. aeruginosa, and in
moderate sputum concentrations showed activity when tested
against BCC complex strains of genomovar I to V. AZLl was
well tolerated in CF patients. The most common adverse events
were increased cough particularly in patients with the highest
dose. Further mild to moderate side effects were chest tightness
and nasal congestion. AZLI sputum concentrations exceeded the
MIC50 for at least 4 h post dose. [58(1b)].
In another double-blind, randomised, placebo-controlled
Phase 2 study [59(1b)], the safety, tolerability and efficacy of
75 mg and 225 mg AZLl, inhaled twice daily for 14 days were
investigated in 105 CF patients with chronic P. aeruginosa
infection. The drug significantly reduced P. aeruginosa CFU
density after 7 and 14 days but did not led to an increased isolation
of S. aureus, B. complex, S. maltophilia, or Alcaligenes
xylosoxidans. FEV1 did not change. AZLI caused a possible
dose-related trend in the incidence and severity of cough in the
higher dose. Therefore, the 75 mg dose thrice daily was tested
against placebo in a Phase 3 study [60(1b)]. Patients in the active
arm showed a significant improvement in clinical symptoms,
percent change in FEV1, and in P. aeruginosa CFU density at
28 days. Adverse events did not differ between the groups.
In a further study, 75 mg of AZLI, inhaled twice or thrice
daily, was tested against placebo [56(1b)] in 246 CF patients. At
day 28, a significant improvement in clinical symptoms, percent
change in FEV1 and in P. aeruginosa CFU density was noted in
both treatment groups and at the end of the 56 day follow-up
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additional inhaled or intravenous antibiotic therapy. Adverse
events did not differ between the groups. In an open-label
follow-up study of 75 mg AZLl twice or thrice daily with an
alternating 28 days on/off design, improvements in patient
reported symptoms, pulmonary function, and P. aeruginosa
CFU density were greater in the thrice daily group (1b). A six-
month Phase 3 comparator study of 75 mg of AZLl thrice daily
against 300 mg of TSI twice daily in a 28-day on/28-day off
design is currently in progress.
2.1.4. Liposomal ciprofloxacin
Ciprofloxacin, a fluoroquinolone which affects gyrase func-
tion in bacteria, has been broadly used by the oral route in
patients with CF and other diseases. Aerosolization of cipro-
floxacin as small particle aerosol or encapsulated in liposomes
into guinea pigs, infected with Legionella pneumophilia [61], or
in mice infected Francisella tularansis [62], prevented the death
of the animals and suggested aerosol delivery to the lower
respiratory tract of CF patients to be effective. When used with
appropriate nebuliser devices liposomal disruption was minimal
[245]. After a successful Phase 1 safety, tolerability and
pharmacokinetic trial in healthy volunteers and a preclinical
toxicology programme currently, a Phase 2 safety and efficacy
study of inhaled liposomal ciprofloxacin in 24 CF patients is
carried out using P. aeruginosa CFU change in sputum as the
primary endpoint. Pharmacokinetic data suggested that once
daily dosing may be possible.
2.1.5. Aerosol MP-376
A formulation of the fluoroquinolone levofloxacin for aero-
sol administration (MP-376) is currently undergoing clinical
evaluation in patients with CF after results in healthy volunteers
have demonstrated that it is well tolerated [63(1b)]. In the single
within-subject ascending dose study of 78, 175 and 260 mg
levofloxacin, there were no serious adverse events or significant
changes in respiratory function between treatment groups and
placebo. Systemic absorption appears to be the major route for
drug elimination from the lungs.
2.1.6. Amphotericin B
Amphotericin B is a widely used antifungal drug with activity
against Cryptococcus neoformans, Candida albicans, A. fumiga-
tus and other species. The drug binds to sterols in the plasma
membranes of fungi, thereby interfering with membrane perme-
ability. Its potentially severe nephrotoxicity and neurotoxicity is a
disadvantage of this drug. A liposomal amphotericin B prepara-
tion (AmBisome®) reduces drug toxicity whilst maintaining
antifungal activity in murine models of pulmonary aspergillosis
[64]; Gilbert et al., 1996). Although nebulised liposomal ampho-
tericin B has been studied in different patient populations, data on
clinical efficacy and tolerability are inconclusive, possibily be-
cause of the lack of uniformity in drug doses and administration
methods [65(1b),66,67(2b),68(2a)].
No controlled trials with nebulised liposomal amphotericin B
have been carried out in CF patients, suffering from A. fumigatus
pulmonary infection. Nebulisation of 50 mg of liposomal am-photericin B once a week, administered by an adaptive aerosol
delivery nebuliser (HaloLite™) in five CF patients suffering
from aggressive bronchopulmonary aspergillosis (ABPA) was
well tolerated, although the 8 ml drug dose required an up to
150 min inhalation period [69(2b)]. In another study, two
persistently infected CF patients became A. fumigatus culture
negative for one to four months after 10 days of treatment with
25mg aerosolized liposomal amphotericin B twice daily [70(4)].
2.2. Mucolytics/mucous mobilizers
2.2.1. Dornase alfa
Dornase alfa inhalation solution is a purified solution of
recombinant human deoxyribonuclease (rhDNase), an enzyme
cleaves sputum DNA, thereby reducing sputum viscoelasticity.
Dornase alfa is used in jet nebulisers (and not in ultrasonic
nebulisers) connected to a compressor. Multiple short and long-
term studies have demonstrated significant improvements in
FEV1 after Dornase alfa treatment compared to placebo in CF
patients [37(1b),71(1b)] and a good tolerance of the drug. Side
effects include voice alteration and rash. In some studies a
significant decrease in the exacerbation rate [37(1b),72(1b)] and
air trapping [73(2b)] was observed. A Cochrane review con-
cluded that dornase alfa improves lung function in short as well
as long-term trials [74(1a)].
In clinical trials device combinations such as Durable
Sidestream® with MOBILAIRE™, Durable Sidestream® with
Porta-Neb®, Hudson TUp-draft II® with Pulmo-Aide®, Respirgard
II Nebulizer® with Pulmo-Aide®, PARI LC PLUS with PARI
PRONEB®, PARI BABY™ with PARI PRONEB® have been
used.
2.2.2. Hypertonic saline
Nebulised hypertonic saline in CF treatment is water for
injection (sterile) with a concentration of 3% to 7% sodium
chloride. Increasing salt concentrations on the luminal side of
the respiratory epithelium is thought to hydrate the viscous
mucus, thereby improving mucociliary clearance and hence
lung function [75(2b)]. Several studies have assessed the effi-
cacy of hypertonic saline in CF patients. A Cochrane review
concluded that nebulised hypertonic saline improves mucocili-
ary clearance in CF patients in short-term clinical trials and
appears to increase lung function compared to control [76(1a)].
In a parallel placebo-controlled trial over 48 weeks, FEV1 and
FVC increased in 82 patients receiving 7% hypertonic saline to
3.2% and 2.8%, respectively, compared to controls [40(1b)].
Hypertonic saline also reduced the percentage of exacerbations
(56%) compared to placebo in this study. In another study, an
increase of FEV1 of 15% was observed after 14 days of treat-
ment with hypertonic saline [77(2b)]. When hypertonic saline
was compared with dornase alfa once daily and on alternate
days in 48 children in an open cross over study, FEV1 increased
in the daily dornase alfa group (16%), followed by alternate day
dornase alfa (14%) and only a modest improvement (3%) in
patients treated with hypertonic saline [78(2b)]. However, large
individual differences in response to dornase alfa and hyper-
tonic saline were found, suggesting that patients should be
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started [79(2b)]. Side effects of nebulised hypertonic saline
include bronchospasm and cough.
2.2.3. Denufosol tetrasodium
Denufosol tetrasodium (Denufusol) inhalation solution is a
selective P2Y2 receptor agonist which activates an alternative
chloride channel [80]. This activation is thought to result in an
increase in the hydration of the respiratory epithelium, thereby
improving mucociliary clearance and lung function. Compared
to UTP and diquafosol, Denufusol shows a prolonged stability
[81–83]. In a phase II study in patients with CF, the aerosolized
drug improved several lung function parameters [84(2b)]. Ad-
verse effects, such as cough and immediate decline in lung
function after inhalation, were similar in the placebo and the
treatment group. Based on these findings, a placebo-controlled
double-blind phase III trial was initiated using 60 mg of
Denufusol over a period of 6 months.
2.2.4. Lancovutide (Moli1901)
Lancovutide (Moli1901) is thought to activate intracellular
calcium in alternative chloride channels, thereby increasing
chloride transport and fluid secretion onto the apical surface of
the airway [85]. Indeed, in a phase II trial, a significant im-
provement of FEV1 was observed by Moli1901 treatment in CF
patients [86]. Aerosolized Lancovutide was well tolerated. The
most frequent adverse events were non-clinically significant
cough and throat irritation. An exploratory multi-center phase
IIb study is currently ongoing in Europe to establish the opti-
mal dose of Moli1901 in CF patients. Patients receive either
placebo, 2.5 mg Lancovutide daily, every other day, or twice
weekly for two months. The primary endpoint is the change in
the percentage of predicted FEV1.
2.3. Inhaled anti-inflammatory therapies
2.3.1. Inhaled corticosteroids
Inhaled corticosteroids are used to reduce endobronchial
inflammation in CF [87,88] and to minimize systemic adverse
effects, experienced with oral prednisolone [89]. In clinical
trials involving CF patients, different doses of budesonide,
beclomethasone or fluticasone propionate (400–1600 µg/day)
were used for treatments of 3 to 52 weeks [90(2b),91(2b),92
(2b),93(2b),94,95(1b),96(2b)]. Decreased bronchial hyperreac-
tivity in non-asthmatic CF patients was observed in two studies
[90(2b),95(1b)].
No study has shown a statistically significant increase in
lung function, although patients receiving beclomethasone for
30 days showed a significant change in DLco (diffusing
capacity for carbon monoxide) [91]. There was no beneficial
change in sputum inflammatory markers [92,93,95] but airway
markers of inflammation fell markedly in lavage fluid [96]. Van
Haren et al. demonstrated small but significant improvements in
daily symptom scores for cough and dyspnoea in a small group
of 12 patients but no improvement in mean overall respiratory
symptom, wellbeing or appetite scores was seen in a larger
study [92].Inhaled corticosteroid treatment was generally well tolerated
and the treatment did not affect urine and blood cortisol, did not
cause any decrease in adrenal reserve or any increase in airway
infection [96]. However, a recent study showed a significant
slowing in linear growth in pre-pubertal children receiving dry-
powder fluticasone propionate over 12 months compared to
placebo [94].
The largest study tested the safety of a withdrawal of cor-
ticosteroid after switching all study patients to fluticasone
inhalation for a two month run in period. Patients were then
randomised to continue fluticasone or start placebo for the next
six months [97(1b)]. There was no difference in the primary
outcome measure of time to first exacerbation between the two
groups, nor in lung function changes, oral or intravenous
antibiotic use, or rescue bronchodilator use. This study supports
the conclusion from the Cochrane review that there is neither
evidence nor benefit or harm from corticosteroid use in CF [98].
The authors suggested that the majority of patients taking
inhaled corticosteroids probably do not need to do so.
2.3.2. Antiproteases
α1-AT and secretory leukoprotease inhibitor (SLPI) are two
endogenous serine protease inhibitors which inactivate neu-
trophil elastase a protease which has been shown to be present
in high concentrations in CF sputum and BALFs [29]. Short-
term aerosol delivery of α1-AT to 12 CF patients suppressed
neutrophil elastase in the epithelial lining fluid and restored
anti-neutrophil elastase capacity [99]. However, a phase II trial
to assess the clinical efficacy and safety of nebulised transgenic
α1-AT did not show any evidence of reduction of airway
inflammation [100(1b)]. In another open short-term study, a
decrease in neutrophil elastase activity, neutrophils, pro-inflam-
matory cytokines and P. aeruginosa numbers was observed,
however, aerosolized α1-AT treatment had no positive effect on
lung function in CF patients [101(2b)]. It is generally agreed, that
studies longer than four weeks in young children with moderate
lung disease are necessary to show potential drug efficacy of
aerosolized α1-AT [102]. Aerosolized SLPI at a dose of 100 mg
twice daily for one week reduced epithelial lining fluid neutrophil
elastase in patients with CF, but 50 mg twice daily for two weeks
were ineffective [103(2b),104(2b)]. The drug has not been further
evaluated in clinical trials.
2.4. Bronchodilators
Inhaled bronchodilators are frequently prescribed for CF
patients with atopy or those who develop airway hyperreactivity
secondary to bronchial damage [105(2b)]. Bronchodilator
therapy may increase mucociliary transport, decrease inflam-
matory damage to the airways, increase exercise tolerance and
decrease dyspnoea [106]. Often the short acting salbutamol or
the long acting salmeterol is used by inhalation.
Most patients show a positive response at some time if
repeatedly treated [107(2b),108(2b)]. However, there are no
long-term controlled trials of inhaled β2-stimulants. A two
month double-blind crossover trial of 90 µg salbutamol four
times daily significantly improved peak expiratory flow rate
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(2b)]. While lung function was not changed in this study,
treatment with inhaled salbutamol (pMDI, 180 µg b.i.d.) sig-
nificantly improved respiratory function in a 12 month obser-
vational study [110(2b)]. However, in a subsequent placebo-
controlled double-blinded trial, CF patients, receiving six
months of 180 µg inhaled salbutamol twice daily, did not differ
significantly compared to placebo in lung function tests [111].
In another study 18% of CF patients, who had salbutamol
showed a significant increase in FEV1 [112(2b)]. Inhaled short-
acting β-agonists did not improve exercise performance or post
exercise dyspnoea in CF patients despite significantly improv-
ing FEV1 [113(1b),114(2b)].
Greater benefits have been reported with the long acting
bronchodilator salmeterol. In an unblinded study [115(4)],
dyspnoea improved even in patients not showing a positive
FEV1 response, when treated with 50 µg salmeterol twice daily
for two weeks. In a 24 week treatment period, 100 µg salmeterol
given twice daily was well tolerated and associated with better
pulmonary function, fewer interventions, and fewer respiratory
symptoms compared to treatment with salbutamol in CF pa-
tients with mild to moderate disease [116(2b)]. Stable CF
patients who responded to day time salbutamol showed sig-
nificant increases in nocturnal oxyhaemoglobin saturation,
following salmeterol administration before sleep [117(1b)]. A
Cochrane review concluded that both short and long acting β-
sympathomimetics can be beneficial in CF patients with
bronchodilator responsiveness or bronchial hyperresponsive-
ness [118(2a)].
Bronchial smooth muscle relaxation may increase airway
compression and reduce cough efficiency by inducing large
airway collapse [119(2b)] but negative responses are unusual
and collapse is unlikely during normal breathing [120(2b),108
(2b)]. No paradoxical responses were found with forced oscil-
lation technique measurements in CF children [121(2b)].
During exacerbations, the efficacy of inhaled bronchodilator
therapy may be reduced [122(2b),107]. However, this concern
has not been confirmed in later studies with inhaled salbutamol
[123] and high dose salmeterol [124(1b)].Table 2
Chemical stability of combinations of inhalation solutions.
Drugs CROMO SAL IPRA COLI TOBRA
CROMO – C [1] a C [1,2] n.d. n.d.
SAL – C [1] C [1] b C [1]
IPRA – n.d. C [1]
COLI – n.d.
TOBRA –
NAC
BUDE
FENO
HTS
DORNA
Drugs: CROM: cromolyn; SAL: salbutamol; IPRA: ipratropiumbromide; COLI: c
budesonide; FENO: fenoterol; HTS: hypertonic saline; DORN: dornase alfa; BENZ
a [References] 1: [134]; 2: [242]; 3: [243]; 4: [246]; 5: [244].
b Preservative-free salbutamol.Also short-term studies of anticholinergic agents have shown
benefit in some CF studies [125(2b),126(2b),127(2b),128(2b)].
However, combinations of β-sympathomimetic and antic-
holinergic drugs did not result in synergistic or additive effects
in CF patients [125(2b),126(2b),127(2b),128(2b)].2.5. Drug combinations
Inhaled drug combinations have been used inCF patients since
nebulisation via a jet nebuliser is generally time-consuming.
Inhaling a mixed drug solution for inhalation saves time.
Also CF patients sometimes refill their nebuliser with
another drug without cleaning in between treatments. Another
objective for inhaled drug combinations is to overcome adverse
effects of one drug by another. An example of the latter case is
bronchoconstriction caused by some antibiotics which can be
overcome by co-administration of salbutamol. The following
drugs have been studied in various combinations: tobramycin,
colistimethate sodium, salbutamol, budesonide, hypertonic
saline, dornase alfa, cromolyn, ipratropium bromide and N-
acetylcysteine.
By mixing different drugs, the following questions arise:
Does mixing affect the physico-chemical stability of the drugs,
their particle-size distribution or the therapeutic outcome?
Which effects have preservatives?2.5.1. Chemical stability and particle-size distribution
The best way to study chemical stability is a visible judge-
ment followed by high-performance liquid chromatography
(HPLC) analysis of the combined solution and a search in
relevant handbooks, e.g., in the Handbook on Injectable Drugs
[129], the Drugdex database [130,131] and The King Guide to
Parenteral Admixtures [130,131]. Table 2 summarizes studies
on chemical stability of mixtures of inhalation solutions.
Stability has been proven for combinations of cromolyn with
salbutamol, ipratropium, N-acetylcysteine and budesonide;
furthermore, combinations of salbutamol with ipratropium,
colistimethate sodium, tobramycin, N-acetylcysteine andNAC BUDE FENO HTS DORNA BENZA
C [1] C [1,2] n.d. n.d. IC IC [1]
C [1] C [1,2] n.d. n.d. IC n.d.
C [3] C [1] C [4] n.d. IC n.d.
C [4] n.d. n.d. n.d. IC IC [1]
n.d. n.d. n.d. n.d. IC n.d.
– n.d. C [3] n.d. IC n.d.
– C [1] n.d. IC n.d.
– n.d. IC n.d.
– IC n.d.
– IC[5]
olistimethate sodium; TOBRA: tobramycin; NAC: N-acetylcysteine; BUDE:
: benzalkonium chloride; C : compatible; IC :incompatible; n.d. : no data.
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with tobramycin, N-acetylcysteine, budesonide and fenoterol or
N-acetylcysteine with fenoterol. N-acetylcysteine is inactivated
by oxygen. This is prevented in the commercial product by
including EDTA, which has no influence on pulmonary
function but is capable of chelating metal ions. EDTA increases
the activity of azithromycin [132] and colistimethate sodium
[133] by chelating divalent cations such as calcium.
Dornase alfa should not be mixed with any other drug for
inhalation due to stability problems of the protein. Sometimes
the preservative and not the pharmacologically active drug
causes an incompatibility. For instance benzalkonium chloride
in combination with colistimethate sodium or cromolyn forms a
hazy cloud [134]. Benzalkonium chloride is present in multi
dose formulations of salbutamol and ipratropium. Benzalk-
onium chloride is a pulmonary irritant and thus preservative-
free solutions are preferred.
Combination of different inhalation fluids may affect particle-
size distribution due to changes in surface tension of the aerosol.
Only one study addressed the aerosol characteristics after mixing
different drugs for inhalation [135]. The authors studied the mean
mass aerodynamic diameter (MMAD), respirable fraction (RF)
and respirable mass (RM) of combinations of salbutamol
(albuterol) and cromolyn, ipratropium bromide, tobramycin,
N-acetylcysteine and flunisolide in continuous nebulisation and in
breath-actuated nebulisation. Most combinations with salbutamol
gave no difference in aerosol characteristics except cromolyn in
continuous nebulisation (MMAD decreases), ipratropium bro-
mide in breath-actuated nebulisation (RM increased), tobramycin
in breath-actuated nebulisation (RF decreased), and flunisolide in
breath-actuated nebulisation (RF and RM decreased). Results
make clear that not only chemical stabilitymust be studied but also
aerosol characteristics, such as is shown in Table 3.
3. Devices for inhaled medication
Basic knowledge on inhalation of drugs will help the pre-
scriber in choosing the right device for each patient. This relatesTable 3
Physico-chemical stability of combinations of inhalation solutions.
Drug Cromolyn Salbutamol Ipratropium
bromide
Colistimethate
sodium
Cromolyn – A B n.d.
Salbutamol – A B
Ipratropium bromide – n.d.
Colistimethate sodium –
Tobramycin
N-acetylcysteine
Budesonide
Fenoterol
Hypertonic Saline
Dornase alfa
A: miscible, grade A evidence, B: miscible, grade B evidence, n.d.: no data, X:
combinations where chemical stability has been proven and aerosol characteristics are
combinations where only chemical stability has been proven without study of aeros
drugs should not be mixed (X).to the dose of the drug, inhaler specifications and patient
characteristics. Table 4 presents a non exhaustive overview of
inhaler specifications versus available inhaler devices.
3.1. Physical parameters
3.1.1. Particle mass, inhaled mass and respirable mass
The particle mass can be described as the fraction of the
nominal dose that leaves the inhaler during inhalation. The
availability of an aerosol is affected by the choice of nebuliser,
volume of fill, residual volume, surface tension of the nebuliser
solution, and the nebulising flow [136]. The inhaled mass is the
fraction of a nebuliser charge that is actually inhaled by the
patient. It is not a fully recognized quality criterion for neb-
ulisers that affects therapeutic efficacy [137]. The inhaled mass
may differ considerably between nebulisers [138]. It is therefore
possible that the effectiveness of an inhaled drug is dependent
on the delivery system. Part of the inhaled mass may be exhaled
again, resulting in a smaller lung dose [139]. An inhaled mass of
the nebuliser charge of approximately 20–40% has been found
in a study with children and adults inhaling isotonic saline
[140]. In CF children, the inhaled mass ranged from 9% to 14%
using a conventional jet nebuliser and 17% to19% using a
Venturi jet nebuliser [141,142]. The inhaled mass can be
measured by putting an inspiration filter on the nebuliser. This
estimated deposition probably differs from real life deposition,
as the latter will be influenced by the particle-size distribution of
the drug, the age and tidal volume of the patient. The amount of
drug on an inspiratory filter may be comparable, while the mass
median aerodynamic diameter (MMAD) of the generated aero-
sol may differ significantly, possibly resulting in central or more
peripheral pulmonary deposition [141,142].
The respirable mass, also called the fine particle fraction, is
the portion of the inhaled mass that is in the particle-size range
expected to bypass the upper airways and deposit in the lower
airways. It is generally considered to consist of particles with an
aerodynamic diameter between 1 and 5 μm and these di-
mensions are thought to result in optimal drug deposition in theTobramycin N-acetyl
cysteine
Budesonide Fenoterol Hypertonic
Saline
Dornase
alfa
n.d. B B n.d. n.d. X
A A B n.d. n.d. X
B B B B n.d. X
n.d. B n.d. n.d. n.d. X
– n.d. n.d. n.d. n.d. X
– n.d. B n.d. X
– B n.d. X
– n.d. X
– X
–
not miscible. The highest grade of evidence for safe combination (A) is for
not altered. The second highest grade of evidence for safe combination (B) is for
ol characteristics. When chemical or physical incompatibility has been proven,
Table 4
Inhaler specifications versus available inhaler devices.
Inhaler specifications Jet Ultrasonic Soft mist,
vibrating mesh
Dry-powder
inhaler (DPI)
Pressured metered dose
inhaler (pMDI)
Evidence-based/based on clinical efficacy studies
in CF patients
Yes Yes No No Yes
For all ages Yes Yes Yes No (for age N6 years) Yes (holding chamber
for infants)
General/generic use; useful for many drugs and/or
disease states
Yes Yes Yes No No
Fast (nebulisation time) No No Yes, intermediate Yes Yes
Small size, easy to carry/portability No No Yes Yes Yes
Noise Yes Yes No No No
External power source (electricity, battery) needed Yes Yes Yes No No
Durability Yes Yes No data Not applicable Not applicable
Price (initial expense) Low-
intermediate
Low-
intermediate
High Low Low
Large fraction of the output of the inhaler has a
particle size of 1–5 micron
Yes/no a Yes/no a Yes Yes Yes
Multiple dose capacity No No No Depends on design Yes
Variable payload possible Yes Yes Yes No No
Breathing coordination required No No No Yes Yes
Useful in tidal breathing/low velocity of the aerosol Yes Yes Yes Yes and no a No; yes (holding chamber)
Dead volume Yes Yes Yes, but generally smaller
than jet/ultrasonic devices
Not applicable Not applicable
High risk on bacterial contamination Yes Yes Yes No data/no b No data b
Preparation and cleaning is easy No No No Yes Yes
Cleaning after each use (bacterial contamination
and maintenance)
Yes Yes Yes No c No c
Periodical maintenance and/or replacement to keep
up efficiency
Yes Yes Yes No No
Adapted from Wolff RK, Niven RW. Generation of aerosolized drugs. J Aerosol Med 1994;7:89. and Rau 2002.
a Depends on device(s) used.
b No data/no: unknown risk in case of a multiple use design/no risk on bacterial contamination in case of disposable design.
c Manufacturers' instructions vary.
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larger particles are predominantly lost because of inertial im-
paction in the oropharynx. Optimal peripheral deposition has
been found to occur with a MMAD of 2–3 μm, combined with
an inhalation flow rate of approximately 15–30 l/min and the
largest inhalation volume convenient for the subject [143,144].
The range of the respirable mass is related to the desired target
area. Relative humidity appears to influence the respirable mass,
depending on the type of nebuliser and the drug solution [145].
3.1.2. Lung dose
The lung dose describes the amount (in mg or fraction of the
nominal dose) of the drug that enters the airways, e.g., passes
the vocal cords. A lung dose can be quoted as a percentage of
the nominal dose, and also as a percentage of the particle mass
or a percentage of the inhaled mass. For example, an intra-
thoracic deposition of ~85% of the emitted aerosol (particle
mass) was measured of which ~77% was deposited in the
peripheral lung [146]. A lung dose can be estimated by
measuring the cumulative excretion of the drug during 24 h in
the urine [147–150] or by radiodeposition studies [139,141,
142,151–159]. For newly developed inhalers, theoretical equi-
valent doses to current, standard inhalation treatment have been
calculated, based on in vitro testing [160,161] or using a doseescalating method [162]. In older studies lung doses ranged
between ~3% to 8% using conventional jet nebulisers [139,140,
151,153]. These percentages improved when newer breath-
enhanced and breath-actuated nebulisers were used: estimated
mean lung doses between 9% and 15% were found using a
PARI LC® Plus–PARI MASTER® combination [163,164], a
Ventstream®–Porta-Neb® combination [165,166], a PARI LC®
Plus–Pulmo-Aide® combination [167] and a PARI LC® Plus or
PARI LL® connected to a PARI BOY® compressor [168].
Ultrasonic nebulisers produce a mean lung dose of ap-
proximately 14%–18% [147,163]. However, also higher mean
lung doses were reported. A mean lung dose of 22% was
estimated using the PARI LC® Star–AKITA® system compared
to 16% for the PARI LC® Star–PARI MASTER® combination
[169]. Comparison of a PARI LC® Plus–PARI BOY® with an
adapted aerosol delivery (AAD) system (HaloLite®) showed a
lung uptake of 20% versus 31% respectively [158]. The de-
livered dose to the lungs with an Aerodose® breath-actuated
inhaler was ~35% versus ~9% with the PARI LC® Plus
nebuliser [170]. A mean lung dose of 32% was measured using
the eFlow® vibrating mesh device compared to 16% using the
PARI LC® Plus–ProNeb® [171]. A lung dose of 63% to 73%
was found with the I-neb® AAD® System [172], expressing a
fraction of the emitted dose.
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mulations using an Aerolizer® capsule inhaler, lung doses of
~53% and ~34% were observed, compared to ~8% using a
PARI LC® Star–PARI TurboBOY® [159]. In a study on lung
deposition of budesonide dry-powder Turbohaler in CF
children, a deposition of 10% to 50% of the inhaled mass was
measured [141,142]. Deposition data of dry-powder formula-
tions relative to liquid nebulisation have been collected [160–
162] but these data do not provide insight into the absolute lung
doses due to the chosen study design. An advantage of dry-
powder inhalation is a reduced loss of aerosolized drug due to
exhalation [159] and leakage.
3.1.3. Output and output rate
3.1.3.1. Jet and ultrasonic nebulisers. Drug output from a jet
or ultrasonic nebuliser is characterized by the generated
particle-size distribution and the particle mass. Drug output
also depends on a number of different variables including the
nebuliser type and the flow rate or (ultrasonic) frequency. A
higher flow results in a higher output rate and a larger drug
output and (central) deposition [173]. Increasing the nebulising
flow also results in a smaller particle-size distribution (MMAD)
and a higher respirable fraction [136,174,175], which may also
improve peripheral lung deposition. However, the total drug
output levels off at a certain point: the optimal inspiratory flow
rate has been found to be ~15 l/min to 30 l/min, depending on
the jet nebuliser used [144,165,166,176–178]. Further variables
are the humidity of the generating gas, temperature, concentra-
tion, viscosity, density, the physical state (solution versus
suspension) and surface tension of the fluid during aerosoliza-
tion [165,166,176,179–183,247]. Importantly the nebuliser
configuration can affect the particle size and the amount of
aerosol inhaled [184]. It has been suggested that the nebuliser
configuration should be precisely specified in treatment
protocols.
Each jet nebuliser has its own resistance, and it is therefore
mandatory to test a nebuliser–compressor combination for
output and flow rate prior to starting therapy. Data on output
rates of compressors, provided by manufacturers, are often
based on a configuration without a nebuliser connected to it.
With an identical driving airflow, the resulting output rate will
differ between various jet nebulisers, as each device has its own
internal resistance. Similarly, ultrasonic devices had a compar-
able or greater output than jet devices when comparing neb-
uliser output with normal saline [183]. Different methods have
been applied to assess drug output rate, which can be expressed
in volume (ml/min) and amount of drug (mg/min). Methods
include weighing a nebuliser [183] or measuring the change in
osmolarity or concentration before and after nebulisation
[178,185]. Additionally, direct measurement of the aerosol on
filters can be used [248,249]. Results from estimating the
aerosolized volume may be misleading when the increase in
drug concentration within the nebuliser, caused by evaporation
of the solvent, is not taken into account [185]. Therefore, drug
output rate in mg/min is a better parameter to describe nebuliser
output than ml/min [165,166].3.1.3.2. Other inhalers. Inhaling from a pressurized metered
dose inhaler (pMDI) without a spacer/holding chamber has a
similar principle to jet nebulisation. A high external driving
flow is generated which is responsible for drug output and
output rate. The patient inhales the drug using its own ins-
piratory flow, preferably with good hand–mouth coordination.
Output and output rate from vibrating mesh devices also
depends to some extent on the inhalation technique of the
patient. If using a passive DPI, the inspiratory flow of the
patient is the only driving source for drug release and dispersion
from the inhaler. A DPI has an internal resistance which has to
be overcome by the inspiratory flow. However, this interplay
may be used to guide effective regional drug deposition in the
lung.
3.1.4. Residual volume
3.1.4.1. Jet and ultrasonic nebulisers. The residual volume, or
dead volume, is defined as the volume of solution remaining in the
nebuliser at the endpoint of nebulisation [183], which is typically
in the range of 1 ml to 3 ml [186] or 38% to 61% of a drug dose
[139,141,142,147,187], depending on the nebuliser used. Small
doses are especially affected. The residual volume depends on the
design of the nebuliser, particularly the extent of the internal
surface, the surface tension, the viscosity of the drug solution and
the wetness of the nebuliser [181,186,188]. A higher fill volume
may reduce the relative extent of the residual volume [203]. The
drug loss may also be decreased and the output improved by
tapping the nebuliser [186]. Residual volumes of ultrasonic
nebulisers are often larger than for jet nebulisers [181].
3.1.4.2. Other inhalers. Residual volumes in novel electro-
nically operated vibrating mesh devices are generally lower
than traditional nebulisers. The residual volume of the I-neb®
AAD® system is approximately 0.1 ml [189]. The residual
volumes in percentage of the nominal dose depend on the fill
volume (0.25–1.4 ml) of the devices. No clinical observations
on residual volume are available. The eFlow® Rapid has a
residual volume of ~1 ml, while ~28% of the drug dose was
found in a clinical study with the eFlow® [171,190]. In general,
powder retention in dry-powder inhalers is low, minimising
drug wastage.
3.1.5. Particle-size distribution
3.1.5.1. Jet and ultrasonic nebulisers. The particle-size
distribution of an aerosol is to a great extent defined by the
design and operating principle (f.e. jet or ultrasonic technique)
of the nebuliser. Additionally, it depends on the applied driving
air flow or ultrasonic frequency, the inspiratory flow generated
by the patient, the temperature of the solution and the physical
characteristics of the nebulised drug [165,166,184]. Manufac-
turer's data on particle-size distribution are frequently based on
normal saline solution, and nebulising drug solutions may result
in altered particle-size distribution [141,142,168,191–193] and
variable administration times. Due to a lower surface tension,
colistimethate sodium tends to foam during nebulisation,
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activity [137,154,155,183]. Due to this foaming, administration
of colistimethate sodium with an ultrasonic nebuliser is pro-
blematic [183].
3.1.5.2. Other inhalers. Some important parameters that
affect drug dispersion from a DPI are the inhaled flow rate
[159,194], the inhaled volume and the internal resistance of the
device [195]. Large fine particle fractions with a peripheral
deposition of approximately 10–20% have been found using a
newly developed DPI [159]. No similar data have been pub-
lished to date on the newer electronically operated devices, like
the I-neb AAD® and eFlow®.
3.1.6. Polydisperse and monodisperse aerosols
The majority of drug aerosols have a polydisperse, asym-
metrical distribution, according to the log-normal law [137].
Monodisperse aerosols have uniformly sized particles with a
narrow size distribution, which can be imitated with a poly-
disperse aerosol, as both distributions are comparable provided
the width of the distribution is not too large (σgb2) [144].
Hygroscopic changes in particle size appear to be negligible if
the concentration of the monodisperse aerosol is high (Finlay
et al., 1998). Generated at an optimal drug particle size for a
target region in the airways, a monodisperse aerosol might
result in the most effective treatment [196]. Clinical data on the
use of monodisperse aerosols are scarce and these aerosols are
currently not used in the treatment of CF lung disease. However,
they are studied in aerosol research to gain knowledge on
aerosol particle behaviour in vivo [144,197].
3.1.7. Administration time
3.1.7.1. Jet and ultrasonic nebulisers. To define the admin-
istration time of a nebulised drug, an endpoint has to be defined
when aerosolization is finished. In clinical studies, definitions
of endpoints vary including the absence of mist [163,181,187,
198,199], sputtering from the nebuliser [183,200], and the
absence of mist for 10 to 30 s [136,141,142,177,187,192,201–
204].
Others defined three possible end points for nebulisation:
sputtering time, total time and clinical time [187]. Sputtering is
the point when aerosolization becomes erratic. This point in
time corresponds with an 8-fold drop in the total number of
particles, read by a laser diffraction analyzer [205]. Total time is
when production of aerosol ceases and clinical time is some-
where between sputtering and total time and approximates the
point when a patient or therapist typically stops a treatment.
Delivery time by a jet nebuliser may vary when connected to a
compressor compared to hospital dry compressed air [178].
Furthermore, tapping of the nebuliser may introduce greater
subjectivity in the measurement [187]. Delivery time by an
ultrasonic nebuliser may be negatively influenced by a higher
drug concentration or higher viscosity [183]. Determination of
aerosol output and residual volume depends on the definition of
the end of the nebulisation and it is therefore important that this
parameter is clearly defined.3.1.7.2. Other inhalers. The newer electronically operated
nebulisers generally switch off at a point when the dose in the
reservoir is aerosolized or at a set time (i.e., after 10min). However,
it is not clear whether a dose is always completely nebulised within
this time frame, which has been shown with a 6 month old eFlow®
Rapid [206]. A mean nebulisation time of 5 min with the I-neb®
AAD® System was found in a 3-month observation period [207].
DPIs require one or several inhalationmanoeuvres which generally
take about 1 min to 2 min, just as pMDIs.
3.1.8. Drug waste during aerosolization
3.1.8.1. Jet and ultrasonic nebulisers. Using a constant
output jet nebuliser, a substantial part of a nominal drug dose
may be lost because of aerosols, generated during the non-
inspiratory part of the respiratory cycle [140,179]. Since the
introduction of the Venturi-nebulisers/breath-enhanced and
breath-actuated nebulisers, drug delivery has improved con-
siderably [141,142,168,178,193,208,209]. Additionally, drug
loss due to exhalation contributes to drug wastage.
3.1.8.2. Other inhalers. Data on drug wastage in CF patients
using pMDIs, vibrating mesh devices and DPIs are sparse.
Using the eFlow®, ~34% of the nominal dose charge was found
on the expiratory filter [171] and ~1% of the emitted drug dose
(particle mass) was wasted using the I-neb AAD System [172].
3.1.9. General purpose nebuliser
Only drug–device combinations tested in clinical studies for
efficacy and safety, particularly concerning drugs with a small
therapeutic window, should be used by CF patients. This is
especially relevant for jet nebulisers, which often are used with
various compressors, each with its own specification. For new
drugs, characterization of the drug–device combination in a
clinical study is essential for in vitro bridging studies. Bridging
studies may be useful in finding an alternative nebulising device
when the preferred device is unavailable.
There are many general purpose nebuliser devices available
worldwide but availability differs from country to country.
Therefore, pharmaceutical companies, marketing drugs for
inhalation, are responsible to provide evidence-based recom-
mendations for their aerosol device in each country in which the
drug is marketed. The use of inhaled drugs in children should
receive specific attention. A pediatric investigation plan (PIP),
already in use by the EMEA, on drugs for inhalation in CF
should include testing appropriate inhaler devices in combina-
tion with a specific drug in children. Regulatory authorities
should promote the use of specific drug–device combinations
in CF patients and set guidelines for bridging studies [210].
3.2. Bacteriological safety and performance of nebulisers over
time
Cleaning of inhaler devices that are used for aerosolization of
liquids is important for bacteriological safety and to ensure that
the performance is not compromised. As DPIs and pMDIs are
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on wet nebulisers.
3.2.1. Bacteriological safety
Wet nebulisers may become a source of bacterial infection
of the respiratory tract and contamination of home equipment
with bacterial pathogens after suboptimal cleaning procedures
has been documented [211–218]. Reports that CF patients
would have acquired bacterial infections from respiratory
therapy equipment during home use however, are lacking
[219] and bacterial organisms grown from patients' sputum
specimens and the respective devices did not correlate
[214,220] in contrast to another study [215]. Nevertheless,
early P. aeruginosa acquisition in young children was asso-
ciated with the use of aerosolized drugs and clinic exposures
[221]. A low risk of microbial contamination of CF inpatients
with CF pathogens from the interior of a disposable nebuliser
over a 24 h period was reported [222]. Also, the bacterial
flora from environmental sources, for example from tap water
[219,223,224] may contaminate a nebuliser, as well as the
colonising flora of the oropharynx [213]. Importantly,
nebuliser devices should not be shared between CF patients
as this has been associated with the acquisition of B. cepacia
complex strains [225]. Cleaning and drying of nebulising
equipment between uses decrease the risk of acquiring
pathogens, including B. cepacia complex [213,214,220,226].
3.2.2. Performance over time
Without cleaning or proper maintenance between runs, some
nebulisers may require a longer time to complete aerosolization,
although particle-size distribution and output are not necessarily
affected. Unwashed devices fail to produce an optimal aerosol
after long-term use [201]. Patients may assess the functionality
of their devices by visual inspection for mist production, cracks
or leaks, and checking the nebulisation time [201]. In a study
using vibrating mesh-nebulisers, no modification of the
membrane function could be detected [227]. After daily use
for six to twelve months of an eFlow® Rapid nebuliser and a
PARI LC® Plus–PARI TurboBOY® combination, changes in
droplet size distribution and a decrease in output rate were
reported [206].
3.2.3. Cleaning of nebuliser equipment
Soaking and rinsing with tap water [216,217], warm soapy
water [201,216,217,227] and boiling water [219] as well as
using a dish washer [201,219] have been proposed to clean
nebuliser devices. However, P. aeruginosa is only killed at
temperatures of ~70 °C. Sodium hypochlorite, isopropylalcohol
and ethanol (70% to 90%) are effective [36,219], in contrast
with the suboptimal results obtained with acetic acid and
quaternary ammonium salts [228–230]. Drying of the equip-
ment after disinfection is important [213,214,220,226]. Patients
should receive clear, written and oral instructions, about how to
keep the bacterial contamination risk as low as possible
[214,221,220,231] to ensure patient adherence to the cleaning
of the nebulising equipment several times daily. Also, home
visits by nurses have been advocated to improve compliance[214,220]. As a result of improved compliance with cleaning
protocols, bacterial contamination may be prevented or
decreased [232,213].
Disposable nebulisers are frequently re-used to reduce
expenses and for convenience [233]. But the consequences of
long-term use of disposable nebulisers are poorly understood
[215] and suggestions in this context differ widely. For instance,
the nebuliser should be changed every 24 h to reduce the risk of
infection [234]; old plastic tubing and atomizing chambers
should be replaced at six-month intervals [213], or at longer
intervals up to four years [231]. The interior tubes should be
dried with the aid of a compressor, attached to the nebuliser
[233] and the service of equipment once a year is advised [214].
3.3. Patient parameters
3.3.1. Deposition pattern and breathing pattern
Causal relationships between the sites of drug deposition
and the patients' response have been established in diseases
of the respiratory tract [235], but no data exist for cystic
fibrosis. Effective targeting of a given region in the lung, for
instance the peripheral airways, has been defined when N50%
of the total drug deposition occurs in that region [197,144].
Studies with radiolabelled aerosols in CF have measured
regional distribution of deposited aerosol throughout the
lung, but often without a direct relationship to efficacy
[139,156,173]. Ideally, the radiolabel should be tied to the
drug in a 1:1 ratio, to visualize pulmonary drug dispersion
and drug efficacy.
Many factors affect total and regional deposition. The un-
derlying disease process is a major determinant of the final
deposition pattern [236]. The deposition pattern is influenced by
age and by the lung function of the individual patient
[141,142,154,155]. Patients with high FEV1 values tend to
have a more homogeneous distribution in the lung including
peripheral airways than those with a low FEV1 [139]. However,
the total amount of drug in the lung can be equivalent in both
groups of patients. The wide variation of aerosol deposition in
CF patients may, among other parameters, be caused by the
different breathing patterns of patients [139,154,155,201,237].
Indeed, controlled breathing has resulted in a narrower range of
deposition [139].
An optimal inspiratory flow rate (l/min) results in an optimal
deposited dose. The deposition rate is related to the patient's
respiratory rate and the type of nebuliser used. An increased
inspiratory flow rate led to an increased deposition rate with a
breath-actuated nebuliser (Halolite), while such a relation was
not seen with a breath-enhanced (PARI LC® Plus) or a breath-
enhanced/breath-actuated device (AeroEclipse) [178]. Slow and
deep inhalation using adaptive aerosol delivery devices such as
the Akita® or the I-neb® AAD® System may improve the lung
deposition [169,189].
3.3.2. The optimal particle size
Drug particles are characterized by size, shape and density.
Deposition properties of drug particles are described by the
aerodynamic behaviour and geometric standard deviation of the
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are the mechanisms by which inhaled particles from an inhaled
aerosol deposit upon airway surfaces. The overall deposition is
a result of the interaction of these mechanisms. During slow
deep breathing sedimentation is efficient in the peripheral
airways and during rapid breathing inertial impaction is efficient
in the large tracheobronchial passages. Major determinants of
the deposited fraction and distribution of the aerosol in the lung
include the inspiratory flow rate, the particle size and the
inhaled volume. By varying these factors, drug delivery to
specific regions in the lung may be accomplished, while min-
imizing losses in the oropharynx [173]. By controlling the
inhalation flow rate and the inhaled volume, a higher peripheral
deposition and reduced dose variability can be obtained [238].
Because of these variables, the optimal particle size for
peripheral deposition in CF airways is not known and probably
does not exist, as the particle size alone does not determine the
deposition result. Furthermore, penetration of particles in the
CF lung is influenced by a decrease in airway caliber, caused by
airway infection, airway inflammation, by an increased mucus
layer, mucus plugging or a combination of these factors. As a
possible consequence, the optimal particle size may differ
between patients according to the disease state. The impact of
infection and inflammation upon airway caliber has not been
studied systematically in CF patients, [239]. Nevertheless, two
clinical trials have given insight concerning the particle size of
drugs in CF patients. Using dornase alfa, both studies showed a
trend for more improvement in pulmonary function tests with
smaller particles versus larger particles, suggesting that tar-
geting peripheral airways with this drug may be advantageous
[202], Geller et al., 1998).
3.3.3. Infants and small children
It is generally agreed that many therapy strategies for CF
would have the greatest benefit in infants and young
children, before the onset of irreversible lung disease.
However, this patient group is the most challenging to treat
with an aerosol (Geller et al., 1997, Tiddens et al., 2007),
since infants and young children have smaller upper and
lower airways, faster respiratory rates and lower inhaled
volumes. Also, infants tend to prefer nasal breathing, which
may filter the aerosol and reduce the lung dose of the drug.
Some children become fussy or cry during aerosol admin-
istration, which dramatically decreases the lung dose of the
drug (Geller et al., 1997). Even though the lung dose in
infants is several-fold smaller than in older children and
adults, their lungs are also much smaller. Therefore lung
deposition is proportionate to size, [152] so adjusting the
nominal dose for children is not always necessary. As an
example, Rosenberg reported serum tobramycin levels in
young CF children that were similar to those of older
subjects, using the same nominal dose and delivery system
[216]. Pulmonary scintigraphy is probably the most valuable
method for studying deposition of drugs in lungs, also in
young children. In scintigraphic lung deposition studies in
CF infants a ~10-fold lower lung deposition has been
observed compared to adults [240]. Deposition can bereduced by bronchial obstruction and inhalation without a
correct facemask. A mouthpiece must be used as early as
possible when children get older [241].
4. Questions and answers
(Grade of recommendations according to the Oxford
Centre For Evidence Based Medicine Levels of Evidence
(Table 5))
Q1 What are the advantages and disadvantages of inhala-
tion medication in CF patients compared to other
drug administrations?
Advantages:
• Generation of high drug levels in CF airways
• Limited systemic toxicity due to low systemic drug
absorption
• Fast onset of action
• No drug inactivation before reaching the target organ
• Direct drug action on target site
• Suitable for home therapy
Potential disadvantages:
• Uncertainty about drug dose at the target site
• Severely affected lung areas may not be reached
• Drug delivery depends on inhalation technique and
device performance
• Local side effects (e.g., cough, airway narrowing,
hoarseness)
• Variable systemic drug absorption
• Time consuming drug administration
• Need for education and training
• Limited information on drug interactions in the lung
• Specific drugs may need specific delivery devices
• Poor adherence
• Potential pollution of the environment
• Potential device contamination and patient infection
• Need for hygiene control and maintenance of the
equipment
• Limits social functioning
Q2 What are the current indications for inhalation med-
ication in CF?
Current indications, based on level A or B clinical
evidence, include:
• Maintenance therapy for chronic P. aeruginosa infection
• Early eradication therapy for P. aeruginosa
• Improvement of airway hydration
• Improvement of mucus clearance
• Documented bronchial hyperreactivity
Q3 What are optimal endpoints in studies testing the
efficacy of inhaled medication in CF?
The optimal endpoint is survival which is difficult to
test in clinical trials in CF patients. Established surrogate
endpoints are:
• FEV1
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• Quality of lifePotential surrogate endpoints are:• Lung function parameters other than FEV1
• Imaging techniques such as HRCT
• Exercise tolerance
• Markers of lung inflammation
• Prevention of lung infection
Surrogate endpoints have serious limitations. They may
depend on age and disease severity of the included
patients as well as on the drug tested. Only few
exacerbations occur in many CF patients, especially in
those with mild lung disease. The terms pulmonary
exacerbations and stable lung function lack a consistent
definition. Limited information for quality of life can be
obtained in young patients. In general, clinical endpoints
in children below the age of 6 years are difficult to
achieve. Independent of the endpoints chosen, novel
drugs for inhalation should be tested in CF patients,
treated according to the best standards of care.
Q4 Should the effect of inhaled medication be evaluated in
individual patients?
Drugs for inhalation which have obtained market
authorization should be repeatedly monitored in eligible
CF patients with regard to potential side effects and the
need for continuous administration. The treatment with a
given drug should be prescribed for the patient in the way
its efficacy has been determined.
Q5 How should the priority of different inhaled medica-
tions be established?
Inhaled medications are difficult to compare, since there
are only few comparative trials. For drug prioritization,
the level of clinical evidence and the potential benefit for
the patients should be taken into consideration.
Q6 How should the sequence of different inhaled medica-
tions during a treatment session be determined?
Information is limited.Mucus clearance and bronchodilator
therapies should precede antimicrobial treatment by
inhalation. Drug interactions should always be considered.
Q7 Which inhaled antibiotics can be recommended?
Tobramycin [A] and colistimethate sodium [B] prepara-
tions for inhalation are recommended. Microbiological
breakpoints for systemic infections (susceptible, inter-
mediate, resistant) do not predict the clinical efficacy of
inhaled antibiotics [B].
Q8 Should inhaled antibiotics be used on alternate months
or continuously?
The decision between a continuous or alternate month
antibiotic therapy strategy depends on the drug and theclinical status of the patients. Alternate month therapy
reduces the selective antibiotic pressure and may thus
reduce the development of antibiotic resistance, observed
during continuous therapy [B]. Comparative trials be-
tween both strategies are lacking.
Q9 Can microorganisms be eradicated using aerosolized
antibiotics, and if so, is monotherapy as effective as
combination therapy with other aerosolized antibio-
tics or antibiotics administered by other routes?
Eradication of early P. aeruginosa infection and preven-
tion of chronic P. aeruginosa infection can be achieved in
the majority of patients and should be attempted with
aerosolized antibiotics or aerosolized antibiotics com-
bined with oral antibiotics in patients with CF [A].
Different antibiotic regimens have been successful. Due
to lack of comparator studies, it is unclear whether
monotherapy or aerosol/systemic combination therapy is
more effective. Re-occurrence of P. aeruginosa in CF
airways after successful eradication should lead to new
attempts to eradicate the pathogen by using the same or
more intensive therapy strategies [B].
Q10 Should inhaled antibiotic therapy be continued upon
eradication of P. aeruginosa, and if so, for which time
period?
Clinical data supporting continuous use of antibiotics after
eradication of P. aeruginosa in CF airways are lacking.
Regardless of undetectable P. aeruginosa in throat swaps
and negative serum antibody titers against P. aeruginosa,
the administration of inhaled antibiotics may be continued
for longer period of time, in caseP. aeruginosa is suspected
to be present in the sinuses or the small airways [D].
Q11 Is aerosol and intravenous administration of a given
antibiotic drug at the same time superior to the
administration of the drug by either route?
For the treatment of P. aeruginosa infections, antibiotics
could be administered by aerosol and intravenously at the
same time to reach high drug concentrations in the lung
[D]. However, there is no scientific evidence to answer
this question.
Q12 Are novel inhaled antibiotics for the treatment of P.
aeruginosa and other CF-related bacterial pathogens
needed?
For the treatment of P. aeruginosa and other CF-related
bacterial pathogens new developments of inhaled anti-
biotics are urgently needed, since tobramycin and colis-
timethate sodium are not sufficiently effective and are not
tolerated by all CF patients.
Q13 Should inhaled corticosteroidal drugs be used for the
treatment of CF lung inflammation and how effective
are they?
Inhaled corticosteroidal drugs should be considered in CF
patients with clinical diagnosis of concomitant asthma,
Table 5
Grades of recommendations.
A Good scientific evidence suggests that the benefits of the clinical
service substantially outweigh the potential risks. Clinicians should
discuss the service with eligible patients (consistent level 1 studies).
B At least fair scientific evidence suggests that the benefits of the
clinical service outweigh the potential risks. Clinicians should discuss
the service with eligible patients (consistent level 2 or 3 studies
or extrapolations from level 1 studies).
C At least fair scientific evidence suggests that there are benefits provided
by the clinical service, but the balance between benefits and risks are
too close for making general recommendations. Clinicians need not offer
it unless there are individual considerations (level 4 studies or
extrapolations from level 2 or 3 studies).
D At least fair scientific evidence suggests that the risks of the clinical
service outweigh potential benefits. Clinicians should not routinely offer
the service to asymptomatic patients (level 5 evidence or troublingly
inconsistent or inconclusive studies of any level).
E Scientific evidence is lacking, of poor quality, or conflicting, such that the
risk versus benefit balance cannot be assessed. Clinicians should help
patients understand the uncertainty surrounding the clinical service.
Ref: Oxford Centre for Evidence-based Medicine Levels of Evidence (May
2001).
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3 month treatment is recommended [D]. Regular anti-
inflammatory therapy, regardless of symptoms, is not
recommended [A]. Inhaled corticosteroidal drugs can be
safely withdrawn even in CF patients who have been
treated for years, and who are not symptomatic. It is
recommended to reduce the dose of inhaled corticoster-
oidal drugs or withdraw the drug whenever possible,
particularly when clinical benefit has not been demon-
strated [A]. There is no clinical evidence for the benefit of
the use of inhaled corticosteroidal drugs in aggressive
bronchopulmonary aspergillosis in CF patients.
Q14 Should the use of recombinant human DNase be
recommended for CF patients regardless of age and if
not, which criteria should be used for implementing
this treatment strategy?
CF patients ≥6 years with mild, moderate and severe
lung disease should be treated with recombinant human
DNase [A]. Evidence for efficacy is lacking in patients
b6 years of age.
Q15 Should the use of hypertonic saline be recommended
for CF patients regardless of age and if not, which
criteria should be used for implementing this treat-
ment strategy?
CF patients ≥6 years should be treated with hypertonic
saline for short-term use to improve lung function [A] and
for long-term treatment to improve lung function, reduce
exacerbations [B] and improve the quality of life.
Evidence for efficacy is lacking in patients b6 years of
age. Clinical trials comparing the established dose of 7%
saline in 4 ml, twice daily, to lower concentrations or less
frequent dosing have not been performed. The therapeutic
effect of hypertonic saline differs from the mode of action
of recombinant human DNase and therefore the two drugs
cannot replace each other.
Q16 Which CF patients should be treated with
bronchodilators?
For CF patients with persistent wheeze or exercise-
induced bronchospasm, potentially suffering from CF
asthma, who experience symptomatic relief from this
treatment, short-acting bronchodilators should be used
[D]. A significant response to treatment may support
the use of bronchodilators, but responses may be quite
variable. Evidence for benefit from regular use of
bronchodilators prior to physiotherapy is lacking.
Evidence for a sustained benefit on mucociliary
clearance is lacking. Bronchodilators may be necessary
before inhaled antibiotics and hypertonic saline are
administered [B]. Long-acting bronchodilators should
be used in CF patients with asthma who cannot be
controlled with short-acting bronchodilators and
inhaled corticosteroids alone [A]. There is insufficient
evidence to support the use of short-acting antic-
holinergic agents.Q17 Should systemic absorption of marketed inhaled
antibiotics be routinely measured and if so, when
and how often should drug levels be measured?
Aminoglycosides: Measurement of serum trough levels
may be performed on a regular basis in CF patients with
reduced renal function, and in CF patients with normal
renal function but at risk for nephrotoxicity (e.g., potential
nephrotoxic co-medication such as non-steroidal anti-
inflammatory drugs and immunosuppressants). Colisti-
methate sodium cannot bemeasured in routine laboratories.
Q18 What tests are required before a new inhalation device
is introduced for use in CF patients?
The introduction of a new inhalation device must be
accompanied by clinical comparative studies, including
the medications recommended by the manufacturer. The
design of such studies is dependent on the drug.
Q19 Can drugs for inhalation be mixed in one device?
It is not recommended to mix medications for inhalation
prior to their use. If mixing is needed, the mixture should
have been tested for chemical and physical compatibility.
Q20 How should a new medication for inhalation be tested
before its use in CF patients.
Safety studies in animals and phase I, II and III studies
should be performed according to regulatory require-
ments. New medications for inhalation should be tested
for pharmacokinetics, including systemic absorption,
safety and efficacy, in young CF children, in adequate
numbers, and in CF adults. Studies should always be
performed using combination(s) with predefined device
(s). As drug concentrations are highly variable in sputum
specimens, they are likely to be the wrong parameter for
pharmacokinetics, peripheral drug deposition and
efficacy.
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